Bayer’s admission of ‘mistake’ underscores FDA’s struggles

A Bayer admission that it "mistakingly" did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency's struggle to get critical drug safety information out to the public.

James G. Dickinson

November 1, 2006

5:00 am

A Bayer admission that it “mistakingly” did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency’s struggle to get critical drug safety information out to the public. FDA had to replace a news release hours after it was issued to reflect new data.

From the November 01, 2006 Issue of MM+M - Medical Marketing and Media

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.